Item 8.01 Other Events.
On April 20, 2021, Kindred Biosciences, Inc. ("KindredBio") issued a press
release announcing positive results in a new long-acting interleukin (IL)-31
antibody program (KIND-039) that integrates KindredBio's novel half-life
extension technology. A copy of the press release is attached to this Current
Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
Exhibit No. Description
99.1 Press Release of Kindred Biosciences, Inc. issued on April 20 ,
2021
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses